Global Halitosis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The halitosis market size is expected to grow from USD 14.41 billion in 2025 to USD 15.93 billion in 2026 and is forecast to reach USD 26.36 billion by 2031 at 10.58% CAGR over 2026-2031. This report is Segmented by Product Type (Antimicrobial Mouthrinses, Toothpaste & Oral Gels, Probiotic Sprays & Lozenges, Chewing Gum & Mints), Drug Class (Antiseptics, Zinc & Metal Ion Formulations, and More), Indication (Intra-Oral Causes, Extra-Oral Causes), End User (Dental Clinics, Hospitals, Homecare), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Halitosis Market Trends and Insights

Rising prevalence of periodontal disease & poor oral hygiene

Severe periodontitis affected more than 1 billion people in 2024 and could reach 1.56 billion by 2050, enlarging the addressable base for the halitosis market. Western sub-Saharan Africa and Qatar post the world’s highest incidence among young adults, underscoring unmet therapy needs in emerging economies. Laboratory work reveals how Fusobacterium nucleatum and Streptococcus gordonii synergistically boost methyl-mercaptan, a principal malodor culprit. Social determinants - low income and limited dental access - strongly influence disease burden, directing demand toward affordable zinc rinses and probiotic tablets.

Growing geriatric population with xerostomia-linked halitosis

Thirty percent of adults aged 65 plus report chronic dry mouth, a problem worsened by more than 400 xerogenic medications. Oral frailty now affects one quarter of seniors worldwide, and the WHO lists 280 million older adults living with untreated oral disorders. Diabetes compounds risk; diabetic seniors show 20.4% caries prevalence versus 18.6% in non-diabetics. Assisted-living centers in the United States, Canada, and Germany have started routine breath screening, boosting institutional sales of moisturizing mouth-sprays.

Chlorhexidine-related taste alteration & tooth-staining

Chlorhexidine rinses increase buccal-cell micronuclei and trigger bitter aftertaste plus brown staining, undermining adherence. Black tea or red wine worsen discoloration, though adding milk halves stain persistence. Hyperpure chlorine dioxide and zinc-ion rinses show comparable antimicrobial efficacy without sensory drawbacks. Honey mouthwash trials confirm equivalent plaque reduction but much lower adverse-effect incidence, steering dentists toward natural alternatives.

Other drivers and restraints analyzed in the detailed report include:

• Proliferation of OTC oral-care SKUs via e-commerce platforms
• Breakthrough oral microbiome probiotics & synbiotics
• Absence of reimbursement / clinical guidelines for halitosis

Segment Analysis

Antimicrobial mouthrinses delivered 53.78% of the halitosis market size in 2025, benefiting from instant volatile-sulfur suppression and dentist endorsements. Listerine Clinical Solutions supplies 67% more zinc than leading peers, promising 24-hour freshness in double-blind trials. Toothpastes and gels rank second, as daily habit loops drive volume; probiotic SKUs add a premium tier. Probiotic sprays and lozenges post the fastest 15.12% CAGR; clinical data show 50% odor reduction over eight weeks. Chewing gum and mints maintain steady demand thanks to portability. Collectively, diversified portfolios cushion the halitosis market against single-category volatility.

Chlorhexidine antiseptics still comprise 40.42% of 2025 sales value but face headwinds on safety perception. Zinc-ion formulations cut malodor without staining, adding share swiftly. Hyperpure chlorine dioxide demonstrated non-inferiority to 0.12% chlorhexidine in 2024 clinical work. Enzyme-activated rinses and peptide antimicrobials such as ε-poly-L-lysine achieved 50.3% volatile-compound reduction versus 32.1% for standard rinses. Expect metal-ion and oxygenating classes to outgrow the overall halitosis market by roughly 250 basis points through 2031.

Complete Report Scope:

• By Product Type
  • Antimicrobial Mouthrinses
  • Toothpaste & Oral Gels
  • Probiotic Sprays & Lozenges
  • Chewing Gum & Mints
• By Drug Class
  • Antiseptics (Chlorhexidine, CPC)
  • Zinc & Metal Ion Formulations
  • Chlorine Dioxide & Chlorite
  • Others (e.g., Oxygenating Agents)
• By Indication
  • Intra-Oral Causes
  • Extra-Oral Causes
• By End User
  • Dental Clinics
  • Hospitals
  • Homecare
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • APAC
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of APAC
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America controlled 41.85% of global sales in 2025, supported by venture-capital inflows of USD 400.2 million into oral-tech startups. US employers bundle breath checks into workplace wellness, driving corporate-bulk orders. Canada benefits from pilot reimbursement for low-income seniors.

Asia-Pacific represents the fastest-expanding halitosis market, poised for a 12.67% CAGR through 2031. China’s probiotic adoption accelerates thanks to nutraceutical-friendly rules, while Japan’s workforce embraces app-linked sensors. India’s health-supplement boom at 20.35% CAGR and ASEAN harmonization smooth cross-border product launches.

Europe remains a mature yet opportunity-rich arena: aging populations, strong universal coverage, and clinician pushback against chlorhexidine staining encourage zinc and probiotic alternatives. South America and Middle East & Africa together deliver double-digit growth, driven by urbanization and wider dental insurance uptake. Pack sizes and price points are localized - 100 ml sachets and herbal rinses - to match purchasing power yet retain efficacy.

List of Companies Covered in this Report:

• Colgate-Palmolive Company
• Procter & Gamble
• Johnson & Johnson (Listerine)
• GlaxoSmithKline
• Church & Dwight Co. (TheraBreath)
• Dr. Harold Katz, LLC
• Rowpar Pharmaceuticals Inc.
• Abbott Laboratories
• Lion
• Sunstar Suisse
• Blis Technologies Ltd.
• Hawley & Hazel (Darlie)
• Reckitt Benckiser Group
• Kao Corporation
• 3M
• Himalaya Wellness Co.
• Dabur India Ltd.
• Henkel
• Unilever plc
• GC Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support